| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3724 |
| Trial ID | NCT06213636 |
| Disease | Acute Lymphoblastic Leukemia | B-Cell Non-Hodgkin's Lymphoma | Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells|EB-BH2024 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | T-cell Infusion Targeting CD19 and CD22 for Refractory/Relapsed Leukemia/Lymphoma Patients With or Without Central Nervous System Involvement |
| Year | 2024 |
| Country | China |
| Company sponsor | Essen Biotech |
| Other ID(s) | ESBI202491 |
| Cohort 1 | |||||||||||
|
|||||||||||